Immunotherapy with antigen-specific T cells is a promising, targeted therapeutic option for patients with cancer as well as for immunocompromised patients with virus infections. In this review, we characterize and compare current manufacturing protocols for the generation of T cells specific to viral and non-viral tumor-associated antigens. Specifically, we discuss: (1) the different methodologies to expand virus-specific T cell and non-viral tumor-associated antigen-specific T cell products, (2) an overview of the immunological principles involved when developing such manufacturing protocols, and (3) proposed standardized methodologies for the generation of polyclonal, polyfunctional antigen-specific T cells irrespective of donor source. Ex vivo expanded cells have been safely administered to treat numerous patients with virus-associated malignancies, hematologic malignancies, and solid tumors. Hence, we have performed a comprehensive review of the clinical trial results evaluating the safety, feasibility, and efficacy of these products in the clinic. In summary, this review seeks to provide new insights regarding antigen-specific T cell technology to benefit a rapidly expanding T cell therapy field.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171249 | PMC |
| http://dx.doi.org/10.1016/j.ymthe.2022.02.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients.
Cancers (Basel)
June 2024
Laboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.
Article Synopsis
- * A study involving 52 stage III/IV NSCLC patients showed that 44% had detectable pre-existing T cells specific to tumors, and those patients had better median overall survival rates compared to those without these T cells.
- * The research highlighted that patients with pre-existing T cells and low levels of certain immunosuppressive cells had a significant survival advantage, suggesting that evaluating these immune cell characteristics could help identify which patients are likely to benefit most from immunotherapy.
Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.
Cytotherapy
November 2024
Cell Therapy Center, Beijing Institute of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, and Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China; Center of Neural Injury and Repair, Beijing Institute for Brain Disorders, Beijing, China. Electronic address:
Article Synopsis
- CAR-T cells, which are engineered to target specific antigens, struggle to effectively treat solid tumors like high-risk neuroblastoma due to various challenges, including poor persistence and diverse antigen expressions.
- A new strategy combining CAR-T cells targeting GD2 and GPC2 was developed to enhance treatment effectiveness by using a selective domain that boosts T cell activity when stimulated by a specific antibody.
- Results showed that this combination therapy improved both the immediate and long-term anti-tumor response in laboratory studies, providing hope for better outcomes in treating this aggressive pediatric cancer.
Tumor-associated antigen-specific cell imaging based on upconversion luminescence and nucleic acid rolling circle amplification.
Mikrochim Acta
April 2024
Center for Molecular Recognition and Biosensing, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China.
Tumor-associated antigen (TAA)-based diagnosis has gained prominence for early tumor screening, treatment monitoring, prognostic assessment, and minimal residual disease detection. However, limitations such as low sensitivity and difficulty in extracting non-specific binding membrane proteins still exist in traditional detection methods. Upconversion luminescence (UCL) exhibits unique physical and chemical properties under wavelength near-infrared light excitation.
View Article and Find Full Text PDFCirculating tumor-associated antigen-specific IFNγ4-1BB CD8 T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancer.
Front Immunol
April 2024
Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
CD8 T cells affect the outcomes of pancreatic ductal adenocarcinoma (PDAC). Using tissue samples at pre-treatment to monitor the immune response is challenging, while blood samples are beneficial in overcoming this limitation. In this study, we measured peripheral antigen-specific CD8 T cell responses against four different tumor-associated antigens (TAAs) in PDAC using flow cytometry and investigated their relationships with clinical features.
View Article and Find Full Text PDFimmunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I interferon combination therapy.
Oncoimmunology
January 2024
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bacteria-based cancer therapy employs various strategies to combat tumors, one of which is delivering tumor-associated antigen (TAA) to generate specific immunity. Here, we utilized a poly-arginine extended HPV E7 antigen (9RE7) for attachment on Salmonella SL7207 outer membrane to synthesize the bacterial vaccine Salmonella-9RE7 (Sal-9RE7), which yielded a significant improvement in the amount of antigen presentation compared to the previous lysine-extended antigen coating strategy. In TC-1 tumor mouse models, Sal-9RE7 monotherapy decreased tumor growth by inducing E7 antigen-specific immunity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!